# A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

> **NCT03680105** · PHASE1 · COMPLETED · sponsor: **Reven Pharmaceuticals, Inc.** · enrollment: 76 (actual)

## Conditions studied

- Critical Limb Ischemia

## Interventions

- **DRUG:** RJX
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03680105
- **Lead sponsor:** Reven Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-24
- **Primary completion:** 2019-01-15
- **Final completion:** 2019-01-15
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2020-04-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03680105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03680105, "A Safety and Tolerability Study of RJX Drug Product in Healthy Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03680105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*